Photo taken from Karine Tawagi/Twitter
Nov 19, 2023, 16:51
Karine Tawagi: New U.S. FDA approval for Enzalutamide in BCR prostate cancer
Karine Tawagi, Assistant Professor of Clinical Medicine and Associate Program Director at the University of Illinois, Chicago, recently shared on X/Twitter:
“New U.S. FDA approval for Enzalutamide in BCR prostate cancer:
– Patients with BCR post-prostatectomy and/or RT, PSA DBT <=9 months, not candidate for salvage RT.
– MFS at 5 years: 87.3% for enzalutamide/ADT vs 80.0% for Enzalutamide alone vs 71.4% for ADT alone.
– OS immature
– AEs: hot flash, MSK, fatigue.”
Source: Karine Tawagi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56